Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28,682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.
Rello J, Nieto M, Solé-Violán J, Wan Y, Gao X, Solem CT, De Salas-Cansado M, Mesa F, Charbonneau C, Chastre J. Rello J, et al. Among authors: gao x. Med Intensiva. 2016 Nov;40(8):474-482. doi: 10.1016/j.medin.2016.01.007. Epub 2016 Apr 6. Med Intensiva. 2016. PMID: 27061776 Free article. English, Spanish.
Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
Niederman MS, Chastre J, Solem CT, Wan Y, Gao X, Myers DE, Haider S, Li JZ, Stephens JM. Niederman MS, et al. Among authors: gao x. Clin Ther. 2014 Sep 1;36(9):1233-1243.e1. doi: 10.1016/j.clinthera.2014.06.029. Epub 2014 Jul 25. Clin Ther. 2014. PMID: 25066668 Clinical Trial.
Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study.
Wan Y, Li Q, Chen Y, Haider S, Liu S, Gao X. Wan Y, et al. Among authors: gao x. J Med Econ. 2016;19(1):53-62. doi: 10.3111/13696998.2015.1088448. Epub 2015 Oct 22. J Med Econ. 2016. PMID: 26490296 Free article. Clinical Trial.
Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
Ostermann H, Solano C, Jarque I, Garcia-Vidal C, Gao X, Barrueta JA, De Salas-Cansado M, Stephens J, Xue M, Weber B, Charbonneau C. Ostermann H, et al. Among authors: gao x. BMC Pharmacol Toxicol. 2014 Sep 24;15:52. doi: 10.1186/2050-6511-15-52. BMC Pharmacol Toxicol. 2014. PMID: 25253630 Free PMC article.
Indirect costs associated with metastatic breast cancer.
Wan Y, Gao X, Mehta S, Wang Z, Faria C, Schwartzberg L. Wan Y, et al. Among authors: gao x. J Med Econ. 2013 Oct;16(10):1169-78. doi: 10.3111/13696998.2013.826228. Epub 2013 Aug 19. J Med Econ. 2013. PMID: 23866016 Free article.
Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt.
Kaci Z, Shalaby L, Kamal S, Boudjerra N, Gao X, Xue M, Ait Belkacem S, Gab Allah Ibrahim A, Kotb R, Charbonneau C. Kaci Z, et al. Among authors: gao x. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):693-700. doi: 10.1080/14737167.2019.1604225. Epub 2019 May 6. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 31055986
28,682 results
You have reached the last available page of results. Please see the User Guide for more information.